News
Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...
Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ...
In a recent transaction, Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc. (NASDAQ: INMB), a company specializing in biological products, has increased his stake in the company by ...
INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...
Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for share ...
INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be ...
Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.
Simultaneously, Inmune Bio has engaged CBIZ CPAs as their new independent registered public accounting firm, effective May 7, 2025, for the fiscal year ending December 31, 2025.
When INmune Bio last reported its balance sheet in December 2019, it had zero debt and cash worth US$7.0m. Importantly, its cash burn was US$5.4m over the trailing twelve months.
INmune Bio Inc. will hold a conference call on June 30, 2025, at 8:00 AM EDT to discuss top line data from its Phase 2 MINDFuL trial in early Alzheimer's Disease.
INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announces that company president and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results